Bacillus Calmette-Guerin

カルメット・ゲラン桿菌

WordNet

1. aerobic rod-shaped spore-producing bacterium; often occurring in chainlike formations; found primarily in soil (同)B

PrepTutorEJDIC

1. バチルス桿菌(かんきん) / (一般に)細菌

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/01/09 19:49:47」(JST)

wiki en

[Wiki en表示]

BCG vaccine

Vaccine description
Target disease	Tuberculosis
Type	Live bacteria
Clinical data
AHFS/Drugs.com	FDA Professional Drug Information
Pregnancy cat.	C (US)
Legal status	℞-only (US)
Routes	Percutaneous
Identifiers
ATC code	J07AN01

Microscopic image of the Calmette-Guérin bacillus, Ziehl–Neelsen stain, magnification:1,000

Bacillus Calmette–Guérin (historically Vaccin Bilié de Calmette et Guérin commonly referred to as Bacille de Calmette et Guérin or BCG) is a vaccine against tuberculosis that is prepared from a strain of the attenuated (weakened) live bovine tuberculosis bacillus, Mycobacterium bovis, that has lost its virulence in humans by being specially subcultured in a culture medium, usually Middlebrook 7H9. Because the living bacilli evolve to make the best use of the available nutrients, they become less well adapted to their traditional environment, human blood, and can no longer induce the disease when introduced into a human host. Still, they are similar enough to their wild ancestors to provide some degree of immunity against human tuberculosis. The BCG vaccine can be anywhere from 0 to 80% effective in preventing tuberculosis for a duration of 15 years; however, its protective effect appears to vary according to geography and the lab in which the vaccine strain was grown.

History

The history of BCG is tied to that of smallpox. Jean Antoine Villemin first recognized bovine tuberculosis in 1854 and transmitted it, and Robert Koch first distinguished Mycobacterium bovis from Mycobacterium tuberculosis. Following the success of vaccination in preventing smallpox, established during the 18th century, scientists thought to find a corollary in tuberculosis by drawing a parallel between bovine tuberculosis and cowpox: it was hypothesized that infection with bovine tuberculosis might protect against infection with human tuberculosis. In the late 19th century, clinical trials using M. bovis were conducted in Italy with disastrous results, because M. bovis was found to be just as virulent as M. tuberculosis.

Albert Calmette, a French physician and bacteriologist, and his assistant and later colleague, Camille Guérin, a veterinarian, were working at the Institut Pasteur de Lille (Lille, France) in 1908. Their work included subculturing virulent strains of the tubercle bacillus and testing different culture media. They noted a glycerin-bile-potato mixture grew bacilli that seemed less virulent, and changed the course of their research to see if repeated subculturing would produce a strain that was attenuated enough to be considered for use as a vaccine. The research continued throughout World War I until 1919, when the now avirulent bacilli were unable to cause tuberculosis disease in research animals. They transferred to the Paris Pasteur Institute in 1919. The BCG vaccine was first used in humans in 1921.

Public acceptance was slow, and one disaster, in particular, did much to harm public acceptance of the vaccine. In the summer of 1930 in Lübeck, 240 infants were vaccinated in the first 10 days of life; almost all developed tuberculosis and 72 infants died. It was subsequently discovered that the BCG administered had been contaminated with a virulent strain that was being stored in the same incubator, and led to legal action being taken against the manufacturers of BCG.

Dr. R.G. Ferguson, working at the Fort Qu'Appelle Sanatorium in Saskatchewan, was among the pioneers in developing the practice of vaccination against tuberculosis. In 1928, BCG was adopted by the Health Committee of the League of Nations (predecessor to the WHO). Because of opposition, however, it did not become widely used until after World War II. From 1945 to 1948, relief organizations (International Tuberculosis Campaign or Joint Enterprises) vaccinated over 8 million babies in eastern Europe and prevented the predicted typical increase of TB after a major war.

BCG is very efficacious against tuberculous meningitis in the pediatric age group, but its efficacy against pulmonary tuberculosis appears to be variable. As of 2006, only a few countries do not use BCG for routine vaccination. The USA and the Netherlands have never used it routinely. In both countries, BCG vaccination is not routinely given to adults because it is felt that having a reliable Mantoux test and being able to accurately detect active disease is more beneficial to society than vaccinating against a condition that is now relatively rare in those countries. Recent research by the Imperial College London has focused instead on finding new cell-wall proteins that trigger an immune response and are suitable for use in a vaccine to provide long-term protection against M. tuberculosis. The study has revealed a few such proteins, the most promising of which has been dubbed EspC; it elicits a very strong immune reaction, and is specific to M. tuberculosis.

Variable efficacy

The most controversial aspect of BCG is the variable efficacy found in different clinical trials, which appears to depend on geography. Trials conducted in the UK have consistently shown a protective effect of 60 to 80%, but those conducted elsewhere have shown no protective effect, and efficacy appears to fall the closer one gets to the equator.

A 1994 systematic review found that the BCG reduces the risk of getting TB by about 50%. There are differences in effectiveness, depending on region due to factors such as genetic differences in the populations, changes in environment, exposure to other bacterial infections, and conditions in the lab where the vaccine is grown, including genetic differences between the strains being cultured and the choice of growth medium.

The duration of protection of BCG is not clearly known. In those studies showing a protective effect, the data are inconsistent. The MRC study showed protection waned to 59% after 15 years and to zero after 20 years; however, a study looking at native Americans immunized in the 1930s found evidence of protection even 60 years after immunization, with only a slight waning in efficacy.

BCG seems to have its greatest effect in preventing miliary TB or TB meningitis, so it is still extensively used even in countries where efficacy against pulmonary tuberculosis is negligible.

Reasons

A number of possible reasons for the variable efficacy of BCG in different countries have been proposed, but none have been proven, and none can explain the lack of efficacy in both low-TB burden countries (US) and high-TB burden countries (India). The reasons for variable efficacy have been discussed at length in a WHO document on BCG.

1. Genetic variation in BCG strains: Genetic variation in the BCG strains used may explain the variable efficacy reported in different trials.
2. Genetic variation in populations: Differences in genetic make-up of different populations may explain the difference in efficacy. The Birmingham BCG trial was published in 1988. The trial, based in Birmingham, United Kingdom, examined children born to families who originated from the Indian Subcontinent (where vaccine efficacy had previously been shown to be zero). The trial showed a 64% protective effect, which is very similar to the figure derived from other UK trials, thus arguing against the genetic variation hypothesis.
3. Interference by nontuberculous mycobacteria: Exposure to environmental mycobacteria (especially M. avium, M. marinum and M. intracellulare) results in a nonspecific immune response against mycobacteria. Administering BCG to someone who already has a nonspecific immune response against mycobacteria does not augment the response already there. BCG will therefore appear not to be efficacious, because that person already has a level of immunity and BCG is not adding to that immunity. This effect is called masking, because the effect of BCG is masked by environmental mycobacteria. Clinical evidence for this effect was found in a series of studies performed in parallel in adolescent school children in the UK and Malawi. In this study, the UK school children had a low baseline cellular immunity to mycobacteria which was increased by BCG; in contrast, the Malawi school children had a high baseline cellular immunity to mycobacteria and this was not significantly increased by BCG. Whether this natural immune response is protective is not known. An alternative explanation is suggested by mouse studies; immunity against mycobacteria stops BCG from replicating and so stops it from producing an immune response. This is called the block hypothesis.
4. Interference by concurrent parasitic infection: In another hypothesis, simultaneous infection with parasites changes the immune response to BCG, making it less effective. As Th1 response is required for an effective immune response to tuberculous infection, concurrent infection with various parasites produces a simultaneous Th2 response, which blunts the effect of BCG.
5. Exposure to ultraviolet light: Concentration of ultraviolet light (particularly UVB light) from the Sun may have some effect on efficacy of the BCG vaccine. UVB has been demonstrated to reduce efficacy of BCG vaccine in laboratory guinea pigs. The concentration gradient of UVB light increases geographically closer to the Earth's equator. Though currently unresearched, this effect possibly occurs as a result of sunlight-dependent vitamin D production.

Uses

Tuberculosis: The main use of BCG is for vaccination against tuberculosis. BCG vaccine can be implemented after the birth intradermally. BCG vaccination is recommended to be given intradermally by a nurse skilled in the technique. A previous BCG vaccination can cause a false positive Mantoux test, although a very high-grade reading is usually due to active disease.

The age of the patient and the frequency with which BCG is given has always varied from country to country.

• WHO BCG policy: The WHO recommend BCG be given to all children born in countries highly endemic for TB because it protects against miliary TB and TB meningitis.
• United States: The US has never used mass immunization of BCG, relying instead on the detection and treatment of latent tuberculosis.
• France: The BCG was mandatory for school children between 1950 (Loi n° 50-7 du 5 janvier 1950) and 2007 (décret n° 2007-1111 du 17 juillet 2007) and for healthcare professionals between 1947 and 2010. Vaccination is still available for French healthcare professionals and social workers but is now decided on a case by case basis.
• United Kingdom: The UK introduced universal BCG immunization in 1953, and until 2005, the UK policy was to immunize all school children at the age of 13, and all neonates born into high-risk groups. The injection was only given once during an individual's lifetime (as there is no evidence of additional protection from more than one vaccination). BCG was also given to protect people who had been exposed to tuberculosis. The peak of tuberculosis incidence is in adolescence and early adulthood, and the MRC trial showed efficacy lasted only 15 years at most. Styblo and Meijer argued neonatal immunization protected against miliary TB and other noncontagious forms of TB, and not pulmonary TB which was a disease of adults, and that mass immunization campaigns with BCG would therefore not be expected to have a significant public health impact. For these and other reasons, BCG was therefore given to time with the peak incidence of pulmonary disease. Routine immunization with BCG was withdrawn in 2005 because of falling cost-effectiveness: whereas in 1953, 94 children would have to be immunized to prevent one case of TB, by 1988, the annual incidence of TB in the UK had fallen so much, 12,000 children would have to be immunized to prevent one case of TB.
• India and Pakistan: India and Pakistan introduced BCG mass immunization in 1948, the first countries outside Europe to do so.
• Brazil: Brazil introduced universal BCG immunization in 1967–1968, and the practice continues until now. According to Brazilian law, BCG is given again to professionals of the health sector and to people close to patients with tuberculosis or leprosy.
• Norway: In Norway the BCG vaccine was mandatory from 1947 to 1995. It is still available and recommended for high-risk groups.
• South Africa: In South Africa, the BCG Vaccine is given routinely at birth, to all newborns, except those with clinically symptomatic AIDS. The vaccination site in the right shoulder.
• Other countries: In some countries, such as the former USSR, BCG was given regularly throughout life. In South Korea, Singapore, Taiwan and Malaysia, BCG was given at birth and again at age 12. But in Malaysia and Singapore, from 2001, this policy was changed to once only at birth.

Method of administration

An apparatus (4–5 cm length, with 9 short needles) used for BCG vaccination in Japan, shown with ampules of BCG and saline

Except in neonates, a tuberculin skin test should always be done before administering BCG. A reactive tuberculin skin test is a contraindication to BCG. Someone with a positive tuberculin reaction is not given BCG, because the risk of severe local inflammation and scarring is high, not because of the common misconception that tuberculin reactors "are already immune" and therefore do not need BCG. People found to have reactive tuberculin skin tests should be screened for active tuberculosis.

BCG is given as a single intradermal injection at the insertion of the deltoid. If BCG is accidentally given subcutaneously, then a local abscess may form (a "BCG-oma") that can sometimes ulcerate, and may require treatment with antibiotics immediately, otherwise without treatment it could spread the infection causing severe damage to vital organs. However, it is important to note an abscess is not always associated with incorrect administration, and it is one of the more common complications that can occur with the vaccination. Numerous medical studies on treatment of these abscesses with antibiotics have been done with varying results, but the consensus is once pus is aspirated and analysed, provided no unusual bacilli are present, the abscess will generally heal on its own in a matter of weeks.

The characteristic raised scar BCG immunization leaves is often used as proof of prior immunization. This scar must be distinguished from that of small pox vaccination, which it may resemble.

Other uses

Micrograph showing granulomatous inflammation of bladder neck tissue due to Bacillus Calmette-Guérin used to treat bladder cancer, H&E stain

• Leprosy: BCG has a protective effect against leprosy in the range of 26 to 41% based on controlled trials. The protective effect is somewhat larger based on case control and cohort studies—about 60%. However BCG vaccine is not used specifically to control leprosy.
• Buruli ulcer: BCG may protect against or delay the onset of Buruli ulcer.
• Cancer immunotherapy/cancer vaccine: A number of cancer vaccines use BCG as an adjuvant to provide an initial stimulation of the patients' immune systems.
  • BCG is used in the treatment of superficial forms of bladder cancer. Since the late 1980s, evidence has become available that instillation of BCG into the bladder is an effective form of immunotherapy in this disease. While the mechanism is unclear, it appears a local immune reaction is mounted against the tumor. Immunotherapy with BCG prevents recurrence in up to 67% of cases of superficial bladder cancer.
  • Colorectal cancer
  • Lung cancer
  • Melanoma
  • MPNST
  • Equine sarcoid (in horses)
• Diabetes, type 1: Clinical trials based on the work of Denise Faustman use BCG to induce production of TNF-α, which can kill the T-cells responsible for type 1 diabetes. In a Phase I, double-blind, placebo-controlled trial, two doses of the BCG vaccine were administered to three adults with long-term type 1 diabetes, resulting in elimination of the pancreas-harming cells, induction of regulatory T cells (Tregs) and a transient rise in C-peptide levels, suggestive of temporarily restored insulin production. Studies using mice have shown a similar treatment results in a permanent cure for about one-third of the test subjects.
• Interstitial cystitis (IC) or painful bladder syndrome (PBS): BCG has been useful in treating some people with IC and/or PBS, which are chronic inflammatory bladder problems with unknown etiology. It is instilled directly into the bladder. How it works is unclear, but is likely immunotherapeutic, as the chronic inflammation could be the result of an autoimmune problem.^{[citation needed]}
• Multiple sclerosis: In humans, BCG has been shown to substantially reduce recurrence of symptoms in multiple sclerosis patients. The frequency of new enhancing lesions as detected by Gd-enhanced MRI was reduced by more than half in 12 patients, comparing the six-month run-in phase to the six-month post-BCG phase of the experiment. Persistence at subsequent MR scan was reduced from 18 lesions to one lesion, and evolution to black holes was reduced from 28 to six lesions. The conventional explanation of such protection is parasites (including bacteria) modulate the sensitivity of the immune system. BCG appears safe as a treatment for multiple sclerosis, although it is not commonly used.
• Parkinson's disease: In a mouse model of Parkinson's disease, BCG vaccination partially preserved striatal dopaminergic markers. The neuroprotective effect is associated with suppression in microglial activation and proliferation in mouse mid-brain area. The neuroprotective effect was later found to be positively associated with regulatory T cell induced by BCG vaccination.

Adverse effects

BCG is one of the most widely used vaccines in the world, with an unparalleled safety record^{[citation needed]}. BCG immunization generally causes some pain and scarring at the site of injection. The main adverse effects are keloids—large, raised scars. The insertion of deltoid is most frequently used because the local complication rate is smallest when that site is used. Nonetheless, the buttock is an alternative site of administration because it provides better cosmetic outcomes.

BCG vaccine should be given intradermally. If given subcutaneously, it may induce local infection and spread to the regional lymph nodes, causing either suppurative and nonsuppurative lymphadenitis. Conservative management is usually adequate for nonsuppurative lymphadenitis. If suppuration occurs, it may need needle aspiration. For nonresolving suppuration, surgical excision is required, but not incision. Uncommonly, breast and gluteal abscesses can occur due to haematogenous and lymphangiomatous spread. Regional bone infection (BCG osteomyelitis or osteitis) and disseminated BCG infection are rare complications of BCG vaccination, but potentially life threatening. Systemic antituberculous therapy may be helpful in severe complications.

If BCG is accidentally given to an immunocompromised patient (e.g., an infant with SCID), it can cause disseminated or life-threatening infection. The documented incidence of this happening is less than one per million immunizations given. In 2007, The WHO stopped recommending BCG for infants with HIV, even if there is a high risk of exposure to TB, because of the risk of disseminated BCG infection (which is approximately 400 per 100,000).

Manufacturers

A number of different companies make BCG, sometimes using different genetic strains of the bacterium. This may result in different product characteristics. OncoTICE, used for bladder instillation for bladder cancer, was developed by Organon Laboratories (since acquired by Schering-Plough, and in turn acquired by Merck, Inc.). Pacis® BCG, made from the Montréal (Institut Armand-Frappier) strain, was first marketed by Urocor in about 2002. Urocor was since acquired by Dianon Systems. Evans Vaccines (a subsidiary of PowderJect Pharmaceuticals Plc, London: PJP). Statens Serum Institut in Denmark markets BCG vaccine prepared using Danish strain 1331. Japan BCG Laboratory markets its vaccine, based on the Tokyo 172 substrain of Pasteur BCG, in 50 countries worldwide. Sanofi Pasteur's BCG vaccine products, made with the Glaxo 1077 strain, were recalled in July 2012 due to noncompliance in the manufacturing process.

Other tuberculosis vaccines

See: Tuberculosis vaccines

See also

• Heaf test
• Mantoux test
• Tuberculosis
• Tuberculosis vaccines
• Philip D'Arcy Hart
• BCG disease outbreak in Finland in the 2000's

References

External links

• Frequently Asked Questions about BCG Professor P D O Davies, Tuberculosis Research Unit, Cardiothoracic Centre, Liverpool, UK.
• BCG World Atlas BCG policy by country, past and present.
• Example of vaccination scars

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 膀胱内BCG免疫療法の合併症 complications of intravesical bcg immunotherapy
• 2. BCG接種 bcg vaccination
• 3. 筋層非浸潤性膀胱癌の治療 treatment of non muscle invasive bladder cancer
• 4. 癌免疫療法の原則 principles of cancer immunotherapy
• 5. ウシ型結核菌 mycobacterium bovis

English Journal

• Understanding the relationship between Mycobacterium bovis spoligotypes from cattle in Latin American Countries.

• Zumárraga MJ, Arriaga C, Barandiaran S, Cobos-Marín L, de Waard J, Estrada-Garcia I, Figueiredo T, Figueroa A, Giménez F, Gomes HM, Gonzalez-Y-Merchand JA, Macías A, Milián-Suazo F, Rodríguez CA, Santillán MA, Suffys PN, Trangoni MD, Zárraga AM, Cataldi A.SourceInstituto de Biotecnología, CICVyA-INTA, Castelar, Buenos Aires, Argentina.
• Research in veterinary science.Res Vet Sci.2013 Feb;94(1):9-21. doi: 10.1016/j.rvsc.2012.07.012. Epub 2012 Aug 9.
• Spoligotyping is the most frequently used method for genotyping isolates of Mycobacterium bovis worldwide. In the current work, we compared spoligotypes from 1684 M. bovis isolates from Argentina (816), Brazil (412), Chile (66), Mexico (274) and Venezuela (116), obtained from cattle, humans, pigs, w
• PMID 22884173

• Mycobacterium bovis vertebral osteomyelitis and discitis with adjacent mycotic abdominal aortic aneurysm caused by intravesical BCG therapy: a case report in an elderly gentleman.

• Samadian S, Phillips FM, Deeab D.SourceCare of the Elderly, St Helier Hospital, Wrythe Lane Carshalton SM5 1AA, UK.
• Age and ageing.Age Ageing.2013 Jan;42(1):129-31. doi: 10.1093/ageing/afs164. Epub 2012 Nov 14.
• The bacille Calmette-Guérin, a live attenuated form of Mycobacterium bovis, has been used as anti-cancer immunotherapy for superficial bladder cancer since 1976 [ 1]. It is now the mainstay of therapy for this condition, which is partly attributable to the low complication rate; indeed 95% have no
• PMID 23151379

Japanese Journal

• 症例報告 BCG膀胱内注入療法後に生じた馬蹄腎結核の1例

• 遠藤 剛,江村 正博,山本 貴大 [他]
• 日本泌尿器科学会雑誌 103(3), 562-565, 2012-05
• NAID 40019256049

• BCG膀胱内注入療法後に結核性前立腺膿瘍をきたした1例

• 橋村 正哉,百瀬 均,武長 真保 [他]
• 泌尿器科紀要 58(3), 169-172, 2012-03
• … We report a case of tubercular prostatic abscess in a male patient who had undergone intravesical Bacillus Calmette-Guerin therapy for bladder carcinoma in situ. …
• NAID 40019204272

Related Links

• Bacillus Calmette–Guérin - Wikipedia, the free encyclopedia

Bacillus Calmette–Guérin (or Bacille Calmette–Guérin, BCG) is a vaccine against tuberculosis that is prepared from a strain of the attenuated (weakened) live bovine tuberculosis bacillus, Mycobacterium bovis, that has lost its virulence in ...

• Bacillus Calmette-Guerin (BCG) for bladder cancer

2 May 2011 ... Drug details for Bacillus Calmette-Guerin (BCG) for bladder cancer.

Related Pictures

---

★リンクテーブル★

リンク元	「カルメット・ゲラン桿菌」

「カルメット・ゲラン桿菌」

　　[★]

英

Bacillus Calmette-Guerin BCG, Calmette-Guerin bacillus

同

マイコバクテリウム・ボビス、Calmette-Guerin桿菌

関

結核、ウシ型弱毒結核菌ワクチン

• 抗酸菌の一種。結核菌と免疫的に交差反応を示すことからワクチンの産生に利用される。
• CalmetteとGuerinがウシ型結核菌(Mycobacterium bovis)を培養してワクチンとして利用できる弱毒株を得た。